ULTRASONICALLY ASSISTED SYNTHESIS OF CHROMEN-2- ONE-1,2,3-TRIAZOLES AND In-vitro ANTICANCER ACTIVITY

Ega, Jagadeesh Kumar; Peddapyata, Prashanth Raja; Kavitha, S.

doi:10.31788/rjc.2023.1618053

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3.08 µM) and was superior to that of cisplatin (IC 50 : 45.33 µM). [97][98][99] Oxime can also serve as a linker, and 1,2,3-triazole-oximecoumarin hybrids 74 (IC 50 : 29.26-53.28 µM, MTT assay) were active against MCF-7 breast cancer cells. [100] The SAR elucidated that the electron-donating group at ortho-position or electron-withdrawing that fluoro on the phenyl ring was favorable to the activity.…”

Section: 23-triazole-azole Hybridsmentioning

confidence: 99%

“…Further study revealed that the amide fragment at the N‐1 position of 1,2,3‐triazole moiety was not essential for the activity, and hybrid 70 (IC 50 : 3.12 µM, MTT assay) was not inferior to doxorubicin (IC 50 : 2.63 µM) against MCF‐7 breast cancer cells; [ 96 ] extension of the carbon spacer between 1,2,3‐triazole and coumarin moieties was tolerated, and hybrids 71 (IC 50 : 2.85 µM, MTT assay), 72a,b (IC 50 : 4.15 and 3.82 µM, MTT assay), and 73 (IC 50 : 2.48 µM, MTT assay) showed potent antiproliferative activity against MCF‐7 breast cancer cells, and the activity was comparable to that of etoposide (IC 50 : 3.08 µM) and was superior to that of cisplatin (IC 50 : 45.33 µM). [ 97–99 ]…”

Section: 23‐triazole‐coumarin/flavonoid Hybridsmentioning

confidence: 99%

See 1 more Smart Citation

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

Song,

Zhang,

Zhang

et al. 2023

Archiv der Pharmazie

View full text Add to dashboard Cite

Breast cancer, as one of the most common invasive malignancies and the leading cause of cancer‐related deaths in women globally, poses a significant challenge in the world health system. Substantial advances in diagnosis and treatment have significantly improved the survival rate of breast cancer patients, but the number of incidences and deaths of breast cancer are projected to increase by 40% and 50%, respectively, by 2040. Chemotherapy is one of the principal treatments for breast cancer therapy, but multidrug resistance and severe side effects remain the major obstacles to the success of treatment. Hence, there is a vital need to develop novel chemotherapeutic agents to combat this deadly disease. 1,2,3‐Triazole, which can be effectively constructed by click chemistry, not only can serve as a linker to connect different anti‐breast cancer pharmacophores but also is a valuable pharmacophore with anti‐breast cancer potential and favorable properties such as hydrogen bonding, moderate dipole moment, and enhanced water solubility. Particularly, 1,2,3‐triazole‐containing hybrids have demonstrated promising in vitro and in vivo anti‐breast cancer potential against both drug‐sensitive and drug‐resistant forms and possessed excellent selectivity by targeting different biological pathways associated with breast cancer, representing privileged scaffolds for the discovery of novel anti‐breast cancer candidates. This review concentrates on the latest advancements of 1,2,3‐triazole‐containing hybrids with anti‐breast cancer potential, including work published between 2020 and the present. The structure–activity relationships (SARs) and mechanisms of action are also reviewed to shed light on the development of more effective and multitargeted candidates.

show abstract

Section: 23-triazole-azole Hybridsmentioning

confidence: 99%

Section: 23‐triazole‐coumarin/flavonoid Hybridsmentioning

confidence: 99%

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

Song,

Zhang,

Zhang

et al. 2023

Archiv der Pharmazie

View full text Add to dashboard Cite

show abstract

The current landscape of coumarin hybrids with antibreast cancer therapeutic applications: An updated review

Wang,

Chen,

Huang

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

Globally, breast cancer (BC) has the highest prevalence among malignant diseases. BC is also the primary cause of death among women. Notably, BC morbidity has been increasing continuously at an approximate growth rate of 2.2% per year. Persistent BC is a major public health issue worldwide. Consequently, novel chemotherapeutic agents to combat this lethal disease should be developed urgently. Coumarins with interesting structural and mechanistic variations exhibit promising activity in several forms of BC, including BCs with multidrug resistance. In particular, coumarin hybrids composed of coumarin and one or more anti‐BC pharmacophores can target different biological components in BC cells simultaneously. Thus, coumarin hybrids are useful scaffolds that can help improve the anti‐BC efficacy of coumarins, reduce side effects, improve pharmacokinetics, minimize drug–drug interactions, and circumvent drug resistance. This review, in which articles published from 2020 to the present day have been evaluated, highlights the landscape of coumarin hybrids that exhibit therapeutic effects against breast cancer. These findings can aid further investigations on novel antibreast‐cancer therapeutics.

show abstract

ULTRASONICALLY ASSISTED SYNTHESIS OF CHROMEN-2- ONE-1,2,3-TRIAZOLES AND In-vitro ANTICANCER ACTIVITY

Cited by 2 publications

References 0 publications

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

The current landscape of coumarin hybrids with antibreast cancer therapeutic applications: An updated review

Contact Info

Product

Resources

About